APA (7th ed.) Citation

Honma, D., Kanno, O., Watanabe, J., Kinoshita, J., Hirasawa, M., Nosaka, E., . . . Adachi, N. (2017). Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor. Cancer science, 108(10), 2069-2078. https://doi.org/10.1111/cas.13326

Chicago Style (17th ed.) Citation

Honma, Daisuke, et al. "Novel Orally Bioavailable EZH1/2 Dual Inhibitors with Greater Antitumor Efficacy than an EZH2 Selective Inhibitor." Cancer Science 108, no. 10 (2017): 2069-2078. https://doi.org/10.1111/cas.13326.

MLA (9th ed.) Citation

Honma, Daisuke, et al. "Novel Orally Bioavailable EZH1/2 Dual Inhibitors with Greater Antitumor Efficacy than an EZH2 Selective Inhibitor." Cancer Science, vol. 108, no. 10, 2017, pp. 2069-2078, https://doi.org/10.1111/cas.13326.